A single nucleotide polymorphism of bone morphogenic protein-15 is not associated with ovarian reserve or response to ovarian stimulation

Human Reproduction

Volumn 29, Issue 12, 2014, Pages 2832-2837

  Cerra, Christian ^a,b   Oliver, Jonathan ^a,b   Roberts, Stephen A ^c   Horne, Gregory ^a   Newman, William G ^b,d   Mohiyiddeen, Lamiya ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

anti Mullerian hormone; bone morphogenic protein 15; follicle stimulating hormone; ovarian response

Indexed keywords

BONE MORPHOGENETIC PROTEIN 15; BUSERELIN ACETATE; FOLLITROPIN; GANIRELIX; GONADORELIN DERIVATIVE; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; MUELLERIAN INHIBITING FACTOR; RECOMBINANT FOLLITROPIN; BMP15 PROTEIN, HUMAN;

ADULT; ALGORITHM; ALLELE; ANTRAL FOLLICLE COUNT; ARTICLE; BLOOD ANALYSIS; BODY MASS; CLINICAL ARTICLE; DNA EXTRACTION; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GENETIC VARIABILITY; GENOTYPE; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; IMMUNOASSAY; INTRACYTOPLASMIC SPERM INJECTION; OBSERVATIONAL STUDY; OOCYTE; OOCYTE RETRIEVAL; OVARIAN RESERVE; OVARY FOLLICLE; PELVIS; PROSPECTIVE STUDY; REGRESSION ANALYSIS; REPRODUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TERTIARY CARE CENTER; TREATMENT OUTCOME; GENETICS; OVULATION INDUCTION;

BONE MORPHOGENETIC PROTEIN 15; FEMALE; GENOTYPE; HUMANS; OVARIAN RESERVE; OVULATION INDUCTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84929649985     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deu264     Document Type: Article

References (27)

1. Abir R, Fisch B. Invited commentary: a single nucleotide polymorphism in BMP15 is associated with high response to controlled ovarian hyperstimulation. Reprod Biomed Online. 2011; 23: 77-80
2. Boudjenah R, Molina-Gomes D, Torre A, Bergere M, Bailly M, Boitrelle F, Taieb S, Wainer R, Benahmed M, de Mazancourt P, et al. Genetic polymorphisms influence the ovarian response to rFSH stimulation in patients undergoing in vitro fertilization programs with ICSI. PLoS One. 2012; 7: e38700
3. de Castro F, Ruiz R, Montoro L, Perez-Hernandez D, Sanchez-Casas Padilla E, Real LM, Ruiz A. Role of follicle-stimulating hormone receptor Ser680Asn polymorphism in the efficacy of follicle-stimulating hormone. Fertil Steril. 2003; 80: 571-576
4. Elvin JA, Clark AT, Wang P, Wolfman NM, Matzuk MM. Paracrine actions of growth differentiation factor-9 in the mammalian ovary. Mol Endocrinol. 1999; 13: 1035-1048
5. Fauser BC, Diedrich K, Devroey P. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update. 2008; 14: 1-14
6. Fortune JE. The early stages of follicular development: activation of primor-dial follicles and growth of preantral follicles. Anim Reprod Sci. 2003; 78: 135-163
7. Galloway SM, McNatty KP, Cambridge LM, Laitinen MP, Juengel JL, Jokiranta TS, McLaren RJ, Luiro K, Dodds KG, Montgomery GW, et al. Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner. Nat Genet. 2000; 25: 279-283
8. Gnoth C, Schuring AN, Friol K, Tigges J, Mallmann P, Godehardt E. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod. 2008; 23: 1359-1365
9. Hanevik HI, Hilmarsen HT, Skjelbred CF, Tanbo T, Kahn JA. A single nucleotide polymorphism in BMP15 is associated with high response to controlled ovarian hyperstimulation. Reprod Biomed Online. 2011; 23: 97-104
10. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1 28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007; 9: 1290-1295
11. Kedem A, Fisch B, Garor R, Ben-Zaken A, Gizunterman T, Felz C, Ben-Harouush A, Kravarusic D, Abir R. Growth differentiating factor 9 (GDF9) and bone morphogenetic protein 15 both activate development of human primordial follicles in vitro, with seemingly more beneficial effects of GDF9. J Clin Endocrinol Metab. 2011; 8: 1246-1254
12. Kevenaar ME, Themmen AP, Laven JS, Sonntag B, Fong SL, Uitterlinden AG, de Jong FH, Pols HA, Simoni M, Visser JA. Anti-Mullerian hormone and anti-Mullerian hormone type II receptor polymorphisms are associated with follicular phase oestradiol levels in normo-ovulatory women. Hum Reprod. 2007; 22: 1547-1554
13. Lakhal B, Laissue P, Braham R, Elghezal H, Saad A, Fellous M, Veitia RA. A novel BMP15 variant, potentially affecting the signal peptide, in a familial case of premature ovarian failure. Clin Endocrinol. 2009; 71: 752-753
14. La Marca A, Sighinolfi G, Argento C, Grisendi V, Casarini L, Volpe A, Simoni M. Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization. Fertil Steril. 2013; 99: 970-978.e1
15. Mohiyiddeen L, Newman WG, McBurney H, Mulugeta B, Roberts SA, Nardo LG. Follicle-stimulating hormone receptor gene polymorphisms are not associated with ovarian reserve markers. Fertil Steril. 2012; 97: 677-681
16. Mohiyiddeen L, Newman WG, Cerra C, McBurney H, Mulugeta B, Roberts SA, Nardo LG. A common Asn680Ser polymorphism in the follicle-stimulating hormone receptor gene is not associated with ovarian response to gonadotropin stimulation in patients undergoing in vitro fertilization. Fertil Steril. 2013; 99: 149-155
17. Morón FJ, de Castro F, Royo JL, Montoro L, Mira E, Saez ME, Real LM, Gonzalez A, Manes S, Ruiz A. Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulating hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS). Pharmacogenet Genomics. 2006; 16: 485-495
18. Olivennes F, Howles CM, Borini A, Germond M, Trew G, Wikland M, Zegers-Hochschild F, Saunders H, Alam V. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online. 2011; 22: S73-S82
19. Otsuka F, Yao Z, Lee T, Yamamoto S, Erickson GF, Shimasaki S. Bone morphogenetic protein-15. Identification of target cells and biological functions. J Biol Chem. 2000; 275: 39523-39528
20. Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab. 2000; 85: 3365-3369
21. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2013. ISBN 3-900051-07-0, http://www.R-project.org/
22. Rossetti R, Di Pasquale E, Marozzi A, Bione S, Toniolo D, Grammatico P, Nelson LM, Beck-Peccoz P, Persani L. BMP 15 mutations associated with primary ovarian insufficiency cause a defective production of bioactive protein. Hum Mutat. 2009; 30: 804-810
23. Shimasaki S, Moore RK, Otsuka F, Erickson GF. The bone morphogenetic protein system in mammalian reproduction. Endocr Rev. 2004; 25: 72-101
24. Simoni M, Nieschlag E, Gromoll J. Isoforms and single nucleotide polymorphisms of the FSH receptor gene: implications for human reproduction. Hum Reprod Update. 2002; 8: 413-421
25. Tiotiu D, Alvaro Mercadal B, Imbert R, Verbist J, Demeestere I, De Leener A, Englert Y, Vassart G, Costagliola S, Delbaere A. Variants of the BMP15 gene in a cohort of patients with premature ovarian failure. Hum Reprod. 2010; 25: 1581-1587
26. vanDisseldorp J, Franke L, Eijkemans R, Broekmans F, Macklon N, Wijmenga C, Fauser B. Genome-wide analysis shows no genomic predictors of ovarian response to stimulation by exogenous FSH for IVF. Reprod Biomed Online. 2011; 22: 382-388
27. Wu YT, Tang L, Cai J, Lu XE, Xu J, Zhu XM, Luo Q, Hunag HF. High bone morphogenetic protein-15 level in follicular fluid is associated with high quality oocyte and subsequent embryonic development. Hum Reprod. 2007; 22: 1526-1531